Final - February 16, 2012 

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) 

Centers for Disease Control and Prevention
 

1600 Clifton Road, NE, Tom Harkin Global Communications Center (Building 19), Kent "Oz" Nelson Auditorium
 

Atlanta, Georgia 30333 

February 22-23, 2012 

AGENDA ITEM PURPOSE 

Wednesday, February 22 2012 

8:00 Welcome & Introductions 

8:30 Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine 

· Introduction 

· Update: resurgence of pertussis disease in the United States 

· Pertussis in older adults in the United States 

· Cost effectiveness of Tdap substitution for Td in prevention 

of pertussis in adults 65 years and older 

Information & 

Discussion 

· Cost effectiveness analysis for Boostrix in adults 65 years of 

age and older 

· Safety and immunogenicity of Tdap in persons 65 years of 

age and older 

· Public comment 

· Proposed recommendation for use of Tdap in persons 65 

years and older 

Vote 

10:30 Break

11:00 Influenza 

· Introduction 

· Update: Influenza activity and vaccines 

· Antiviral medications Information & 

· Future activities Discussion 

· Recommendations (reiteration of recommendation for annual 

vaccination for all 6 months of age and older) 

12:00 Lunch

1:30 13-valent Pneumococcal Conjugate Vaccine (PCV13) 

· Introduction 

· Pneumococcal conjugate vaccine for adults 50 years of age or 

older: background review of data, and GRADE 

· Pneumococcal conjugate vaccine for adults with 

immunocompromising conditions: background, review of data 

and GRADE 

Information & 

Discussion 

3:30 Break

4:00 Hepatitis B Vaccine 

· Introduction 

· Ensuring hepatitis B protection for remotely vaccinated healthcare personnel; overview of issues; ACIP requests for 

information 

Information & 

Discussion 

4:30 Vaccine Supply Information 

4:45 Public Comment 

5:00 Adjourn 

PRESIDER/PRESENTER(s) 

Dr. Carol Baker (ACIP Chair)
 

Dr. Larry Pickering (ACIP Executive Secretary; 

CDC)
 

Dr. Mark Sawyer (ACIP, WG Chair)
 

Dr. Thomas Clark (CDC/NCIRD)
 

Dr. Anna Acosta (CDC/NCIRD)
 

Dr. Anna Acosta (CDC/NCIRD)
 

Ms. Shanthy Krishnarajah (Head, US Health 

Outcomes, GSK)
 

Dr. Jennifer Liang (CDC/NCIRD)
 

Dr. Jennifer Liang (CDC/NCIRD)
 

Dr. Wendy Keitel (ACIP, WG Chair)
 

Dr. Lisa Grohskopf (CDC/NCIRD)
 

Dr. Timothy Uyeki (CDC/NCIRD)
 

Dr. Lisa Grohskopf (CDC/NCIRD)
 

Dr. Lisa Grohskopf (CDC/NCIRD)
 

Dr. Nancy Bennett (ACIP, WG Chair)
 

Dr. Tamara Pilishvili (CDC/NCIRD)
 

Dr. Kathleen Dooling (CDC/NCIRD)
 

Dr. Mark Sawyer (ACIP, WG Chair)
 

Dr. Sarah Schillie (CDC/NCHHSTP)
 

Dr. Jeanne Santoli (CDC/NCIRD)
 

page 1 of 2 
Final - February 16, 2012 

Thursday, February 23, 2012 

8:00 Unfinished Business Dr. Carol Baker (Chair, ACIP) 

8:15 Agency Updates 

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NVPO, NIH Information CDC and Ex officio members 

8:30 Meningococcal Vaccines 

· Introduction Dr. Cody Meissner (ACIP, WG Chair) 

· GRADE (Grading of Evidence) assessment for MenACWY-D 

(Menactra) in children 9-23 months of age 

Information & 

Discussion 

Dr. Elizabeth Briere (CDC/NCIRD) 

· Updates to the Meningococcal Vaccines Statement Dr. Amanda Cohn (CDC/NCIRD) 

10:00 Break

10:30 Measles, Mumps, Rubella (MMR) Vaccine 

· Introduction Dr. Jon Temte (ACIP, WG Chair) 

· Update: measles/rubella elimination consultation and 

documentation 

Dr. Mark Papania (CDC/NCIRD) 

· Impact of a third dose of MMR vaccine on the course of a 

mumps outbreak in an orthodox Jewish community 

· Epidemiology of mumps in the United States Information 

& 

Discussion 

Mr. Albert Barskey (CDC/NCIRD) 

Dr. Preeta Kutty (CDC/NCIRD) 

· Impact of a third dose of MMR vaccine on mumps outbreak 

in Guam and economic impact of the outbreak 

Ms. Amy Parker Fiebelkorn (CDC/NCIRD) 

· Summary of issues and discussion Dr. Huong McLean (CDC/NCIRD) 

12:15 Public Comment 

12:30 Adjourn 

Acronyms

GRADE Grading of Recommendations Assessment, Development and Evaluation 

MenACWY-D Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine 

NCCDPHP National Center for Chronic Disease Prevention and Health Promotion 

NCEZID National Center for Emerging and Zoonotic Infectious 

NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 

NCIRD National Center for Immunization and Respiratory Diseases 

TBD To be determined 

Tdap Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 

WG Work Group 

page 2 of 2